Esri and IBM Team Up to Take on Climate Change with Call for Code
11.5.2021 20:23:00 EEST | Business Wire | Press release
Esri, the global leader in location intelligence, today announced it is joining the fourth annual Call for Code Global Challenge. Created by David Clark Cause and launched in partnership with IBM, United Nations Human Rights, and the Linux Foundation, Call for Code is designed to make an immediate and lasting global impact on humanitarian issues, using open-source-powered technology. In this year’s competition, software developers and innovators around the world will take on climate change with open-source software, including Red Hat OpenShift, IBM Cloud, IBM Watson, IBM Blockchain, and data from The Weather Company.
Since Call for Code was launched in 2018, more than 400,000 developers and problem solvers across 179 nations have participated, creating more than 15,000 applications. This year’s competition focuses on three sub-themes related to combating climate change: water availability and consumption, food production and delivery, and economic production and consumption.
The winning team will receive $200,000 and support from the IBM Service Corps, technical experts, and partners—to develop their technology, make their code available for anyone to use in open-source, and deploy their solution on the ground in communities around the world.
For its role in the Call for Code Global Challenge, Esri has made its geospatial analytics software and resources available to each participant, including the following:
- A free ArcGIS Platform developer account.
- A $100 voucher applied to the participant’s ArcGIS account, allowing them to kick-start their solution with cloud hosting, analytical processing, and location services (This is available to the first 100 participants.)
- Access to dedicated community support where participants can connect with mentors that can help them accelerate app development.
"Esri has just released a location platform as a service product that makes it easy for software developers to access geospatial technology," said David Cardella, Product Manager—Developer Technologies, Esri. "Some of the most exciting ways users are putting our software to work is in creating apps that help meet challenges related to climate change. We are excited to introduce our flexible, scalable location services that make content and capabilities available to developers who are building the next generation of geospatial solutions."
For more information and to learn how to get started on the Call for Code Global Challenge with Esri’s offer, visit the ArcGIS Blog. Watch Kareem Yusuf, General Manager, AI Applications and Blockchain, IBM and Jack Dangermond, Founder and President, Esri, discuss their partnership and the importance of technology to address climate change here.
“We are excited to work with Esri and our global ecosystem throughout the 2021 Call for Code Global Challenge to drive, incubate, and deploy solutions that will combat climate change,” said Willie M. Tejada, IBM Chief Developer Advocate and General Manager ISV/Build Ecosystem. “Climate change is a monumental challenge and demands the participation of world-renowned humanitarian experts, business leaders, and technology partners like Esri to have an immediate and lasting effect.”
What makes Call for Code unique is the impact it is making on the ground through deployments in communities around the world. Last year’s winning solution, Agrolly, was designed to support small farmers by providing climate and crop predictions and recommendations. The agriculture industry is one of the most vulnerable to climate change due to its dependence on rainfall and temperature. Since October, the Agrolly team has expanded the solution to new markets and provided hands-on training to more than 500 rural farmers in Mongolia, India, and Brazil, who are testing and using the app to fight the effects of climate change.
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com.
Copyright © 2021 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
About Call for Code Global Challenge
Developers have revolutionized the way people live and interact with virtually everyone and everything. Where most people see challenges, developers see possibilities. That's why David Clark, the CEO of David Clark Cause, created Call for Code in 2018, and launched it alongside Founding Partner IBM and Charitable Partner UN Human rights. Since then, Call for Code has scaled to include an annual University Challenge in addition to regional prizes and the creation of Call for Code for Racial Justice. This multi-year global initiative is a rallying cry to developers to use their mastery of the latest technologies to drive positive and long-lasting change across the world through code. Call for Code Global Challenge winning solutions are further developed, incubated, and deployed as sustainable open source projects to ensure they can drive positive change. To learn more about past winners and their progress, visit IBM Developer.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511006031/en/
Contact information
Jo Ann Pruchniewski
Public Relations, Esri
Mobile: 301-693-2643
Email: jpruchniewski@esri.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom